Robert Stuart to Cyclophosphamide
This is a "connection" page, showing publications Robert Stuart has written about Cyclophosphamide.
Connection Strength
1.020
-
Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization. Bone Marrow Transplant. 2011 Apr; 46(4):523-8.
Score: 0.339
-
Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchange. Eur J Haematol. 2012 Nov; 89(5):432-4.
Score: 0.099
-
Effectiveness and safety of high-dose cyclophosphamide as salvage therapy for high-risk multiple myeloma and plasma cell leukemia refractory to new biological agents. Am J Hematol. 2011 Aug; 86(8):699-701.
Score: 0.090
-
Role of glutathione in the in vitro synergism between 4-hydroperoxy-cyclophosphamide and cisplatin in leukemia cell lines. Cancer Res. 1991 May 15; 51(10):2536-41.
Score: 0.090
-
Synergism between 4-hydroperoxycyclophosphamide and cisplatin: importance of incubation sequence and measurement of cisplatin accumulation. Biochem Pharmacol. 1990 Feb 01; 39(3):607-9.
Score: 0.082
-
Cellular glutathione as a protective agent against 4-hydroperoxycyclophosphamide cytotoxicity in K-562 cells. Cancer Chemother Pharmacol. 1990; 26(6):397-402.
Score: 0.082
-
In vitro synergism of 4-hydroperoxycyclophosphamide and cisplatin: relevance for bone marrow purging. Cancer Chemother Pharmacol. 1989; 23(3):129-34.
Score: 0.076
-
Human multilineage progenitor cell sensitivity to 4-hydroperoxycyclophosphamide. Exp Hematol. 1985 May; 13(4):295-8.
Score: 0.059
-
Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. Leuk Lymphoma. 2015; 56(9):2569-78.
Score: 0.029
-
Combinations of 4-hydroperoxycyclophosphamide (4-HC) and cisplatin for bone marrow purging in autologous marrow transplantation: an update. Prog Clin Biol Res. 1990; 333:57-68.
Score: 0.020
-
Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N Engl J Med. 1986 Jul 17; 315(3):141-7.
Score: 0.016
-
Autologous bone marrow transplantation in acute leukemia: a phase I study of in vitro treatment of marrow with 4-hydroperoxycyclophosphamide to purge tumor cells. Blood. 1985 Jun; 65(6):1504-10.
Score: 0.015
-
Autologous bone marrow transplantation in acute leukemia and non-Hodgkin's lymphoma: a phase I study of 4-hydroperoxycyclophosphamide (4HC) incubation of marrow prior to cryopreservation. Haematol Blood Transfus. 1983; 28:90-1.
Score: 0.013
-
Adding high-dose tamoxifen to CHOP does not influence response or survival in aggressive non-Hodgkin's lymphoma: an interim analysis of a randomized phase III trial. Med Oncol. 2000 Feb; 17(1):39-46.
Score: 0.010